New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

It’s been a busy week for C4 Therapeutics Inc., which hired a new CEO and filed to go public. Andrew Hirsch is joining the protein degradation company from Agios Pharmaceuticals Inc. (NASDAQ:AGIO), where he has been CFO and head of corporate development; he will succeed co-founder Marc Cohen, who remains executive chairman.

The four-year-old company signalled that an IPO was on the horizon in June, when it raised $150 million in a series B round backed by numerous crossover investors. It filed to raise up to $100 million on NASDAQ, where it would become the fourth protein degradation company to list (see “Crossovers Pile into New Rounds”; “Enthusiasm for Protein Degradation, Preclinical IPOs”)...